fig6
Figure 6. MEKi-induced MHC-I & PD-L1 expression are ErbB family kinase dependent in MMTV-Neu cells. MMTV-Neu murine mammary cells were treated with or without trametinib (50 nM; MEKi) and/or Erlotinib (0.5 µM) or Lapatinib (0.1 µM) for 72 h prior to flow cytometry analysis for MHC-I (H2Kq) and PD-L1 expression. Histogram plots (A) and bar graphs of MFI (B) (n = 3). MEKi: MEK inhibition; DMSO: dimethylsulfoxide
